Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUConn Health
About this trial
The purpose of this research is to determine if two proteins in the blood are increased during acute heart failure. These two proteins are produced when the heart becomes dysfunctional and unable to contract normally. They may then be released into the blood and be detected by standard method in the research laboratory. Thus, the purpose of this study is to determine the relation between the change of these two proteins in the blood and the occurrence of acute heart failure. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or heart failure.
Eligibility criteria
Qualifiers
Individuals aged >18yrs
stable or decompensated heart failure, irrespective of LVEF
decompensated heart failure clinical symptoms such as dyspnea, rales, edema, elevated jugular venous pressure, or ascites
Imaging evidence of heart failure (cardiomegaly, poor contractile function or echocardiographic Doppler evidence of diastolic dysfunction or elevated right- or left-sided filling pressures)
Disqualifiers
Subjects who are unable to give informed consent
Subjects who had undergone cardiac or non-cardiac surgery in the 3 months before enrollment
Pregnant subjects are not excluded
Trial design
Treatments tested in this trial
- Not listed
Trial groups
500 Participants
are grouped into 1 trial groupSponsors and collaborators
UConn Health
Lead sponsor
CT Department of Public Health
Collaborator
Source ClinicalTrials.gov